Entrepreneurial system

Strategic Partnership Between King Saud University Medical City and Takeda

to Enhance Healthcare Training in Saudi Arabia

  • The partnership between King Saud University Medical City and Takeda aims to develop healthcare professionals in Saudi Arabia through knowledge exchange, training initiatives, and scientific research.
  • The collaboration will contribute to the advancement of healthcare through Takeda’s expertise in areas such as oncology, rare diseases, neurology, gastroenterology, as well as plasma-derived therapies and vaccines.
  • The partnership reflects the commitment of both parties to improving patient outcomes and enhancing the resilience of the healthcare system through collaboration in digital health solutions and telemedicine.

Riyadh, Saudi Arabia, January 28, 2025: King Saud University Medical City has signed a strategic partnership with Takeda Pharmaceutical Company to enhance medical training for healthcare professionals in Saudi Arabia.

The partnership focuses on knowledge exchange, training and awareness initiatives, research and development, and collaboration in digital health solutions and telemedicine. It aims to support the development of the healthcare sector in the Kingdom in alignment with the goals of Vision 2030. The memorandum of cooperation was signed on the sidelines of the recently held Global Health Forum at the Riyadh International Convention and Exhibition Center, in the presence of Professor Ahmed bin Salah Hirsi, Executive Director of King Saud University Medical City, and Dr. Khaled Sary, General Manager of Takeda West Gulf.

King Saud University Medical City in Riyadh is a multidisciplinary medical center that brings together a team of experts and utilizes the latest medical technologies. This global medical complex includes more than 1,300 doctors and specialists, 853 residents and fellows, and around 2,072 healthcare support staff. Under this partnership, Takeda will enhance the skills of healthcare professionals at King Saud University Medical City through its global expertise in scientific research and development, and medical innovation in its key therapeutic areas, including oncology, rare diseases, neurology, gastroenterology, infections, plasma-derived therapies, and vaccines.

Commenting on the new partnership, Professor Ahmed bin Salah Hirsi, Executive Director of King Saud University Medical City, said: “Driven by our commitment to enhancing the quality of healthcare for citizens in the Kingdom in alignment with Vision 2030, public-private partnerships will play a crucial role in achieving the key objectives. The collaboration with Takeda will undoubtedly strengthen training initiatives, knowledge development, and the provision of the latest innovations and medical technologies, enabling our healthcare providers to deliver the best possible care for patients.”

On his part, Dr. Khaled Sary, General Manager of Takeda West Gulf, said: “Thanks to our shared values of focusing on patients and innovation, we are confident that our collaboration with King Saud University Medical City will enhance patient care in the Kingdom in terms of diagnosis and treatment. We continue to support the establishment of a more resilient healthcare system that better adapts to the needs of today’s patients, leveraging the local expertise of King Saud University Medical City and Takeda’s global capabilities in research and development.”

With the aim of addressing unmet medical needs and strengthening sustainable healthcare systems, the partnership with King Saud University Medical City embodies Takeda’s commitment to fostering innovation, empowering medical staff, and improving patient outcomes through collaborative efforts across the region. Takeda will continue to prioritize strategic partnerships in the Middle East to improve patient care in the near future.

Related Articles

Back to top button